9.2612

1.17% -0.1088

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $9.2612, with a volume of 495.67K. It is down -1.17% in the last 24 hours and up +19.64% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$9.37

Open:

$9.33

24h Volume:

495.67K

Relative Volume:

0.57

Market Cap:

$1.31B

Revenue:

$57.65M

Net Income/Loss:

$-483.04M

P/E Ratio:

-2.0626

EPS:

-4.49

Net Cash Flow:

$-458.78M

1W Performance:

+21.68%

1M Performance:

+19.64%

6M Performance:

-10.88%

1Y Performance:

+5.71%

1-Day Range:

$9.20

$9.62

1-Week Range:

$7.12

$9.74

52-Week Range:

$7.12

$13.09

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

587

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

11:29 AM

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off (NASDAQ:VIR) - Seeking Alpha

11:29 AM

05:37 AM

VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges - Investing.com

05:37 AM

01:08 AM

Trading (VIR) With Integrated Risk Controls - Stock Traders Daily

01:08 AM

12:44 PM

Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript - MSN

12:44 PM

Nov 04, 2024

HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 04, 2024

Vir Biotechnology (NASDAQ:VIR) Given New $26.00 Price Target at Barclays - MarketBeat

Nov 04, 2024

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 04, 2024

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance

Nov 04, 2024

Nov 02, 2024

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 02, 2024